Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.
ConditionNeuroendocrine Tumors
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorLund University Hospital
About this trial
There are several ways of personalizing PRRT (peptide receptor radionuclide treatment) in NEN (neuroendocrine neoplasia). Nevertheless, the current treatment regimen is not personalized. This trial aims to compare personalized PRRT to non-personalized PRRT in terms of safety, efficacy and resource demands in order to optimize treatment outcomes in an evidence-based manner in future.
Eligibility criteria
Qualifiers
Age ≥18 years
Written informed consent
Eastern Cooperative Oncology Group (ECOG) 0-1
Presence of histologically confirmed, advanced, well-differentiated, inoperable neuroendocrine tumors (NET) of any primary tumor origin and any grade, except for pheochromocytoma and paraganglioma.
Disqualifiers
Pregnancy or lactation
Previous treatment with PRRT
Concomitant systemic anti-tumor therapy other than somatostatin analogue (SSA)
Contraindications for treatment with capecitabine according to the approved label.
Trial design
Treatments tested in this trial
- 177Lu-DOTATOC
- Capecitabine
Treatment groups
300 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov